Literature DB >> 17427169

Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis.

P Minoo1, M P Moyer, J R Jass.   

Abstract

There is increasing evidence for an alternative pathway of sporadic colorectal tumourigenesis that is associated with DNA microsatellite instability (MSI), due to methylation and loss of expression of the mismatch repair gene MLH1. Recent studies have highlighted a serrated pathway of colorectal cancer (CRC) in which serrated polyps with activating mutations in BRAF progress to CRCs with MSI following methylation and silencing of MLH1. The present study provides a novel mechanistic experimental model for these clinical observations. We investigated the role of BRAF activating mutation (BRAF-V600E) in colorectal tumourigenesis by studying the effects of forced expression of BRAF-V600E in the 'normal' colon epithelial NCM460 cell line and by targeting endogenous BRAF-V600E in MSI-High (MSI-H) colon cancer cell lines. The findings indicate that BRAF mutation in colon epithelial cells contributes to a gain in resistance towards apoptotic stimuli, which is likely to be an important characteristic of pre-malignant serrated lesions. BRAF-V600E also plays a role in the development and maintenance of transformed and invasive phenotypes in colon epithelial cells. Our findings also suggest that BRAF mutation potentiates promoter hypermethylation of the MLH1 gene promoter. Together, these results highlight BRAF as a potential target for therapeutic intervention in sporadic MSI-H colorectal cancers. Copyright 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17427169     DOI: 10.1002/path.2160

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  30 in total

1.  Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer.

Authors:  Noriko Tanaka; Curtis Huttenhower; Katsuhiko Nosho; Yoshifumi Baba; Kaori Shima; John Quackenbush; Kevin M Haigis; Edward Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

2.  Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients.

Authors:  Francesc Balaguer; Judith Balmaña; Sergi Castellví-Bel; Ewout W Steyerberg; Montserrat Andreu; Xavier Llor; Rodrigo Jover; Sapna Syngal; Antoni Castells
Journal:  Gastroenterology       Date:  2007-10-26       Impact factor: 22.682

3.  Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling.

Authors:  Toshinori Hinoue; Daniel J Weisenberger; Fei Pan; Mihaela Campan; Myungjin Kim; Joanne Young; Vicki L Whitehall; Barbara A Leggett; Peter W Laird
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

4.  Molecular Prognostic and Predictive Markers in Colorectal Cancer: Current Status.

Authors:  Jeffrey K Lee; Andrew T Chan
Journal:  Curr Colorectal Cancer Rep       Date:  2011-06-01

Review 5.  The third dimension: new developments in cell culture models for colorectal research.

Authors:  Joana F S Pereira; Nikhil T Awatade; Cláudia A Loureiro; Paulo Matos; Margarida D Amaral; Peter Jordan
Journal:  Cell Mol Life Sci       Date:  2016-05-04       Impact factor: 9.261

Review 6.  The GIST paradigm: lessons for other kinase-driven cancers.

Authors:  Cristina R Antonescu
Journal:  J Pathol       Date:  2010-10-26       Impact factor: 7.996

7.  A significant imbalance in mitosis versus apoptosis accelerates the growth rate of sessile serrated adenoma/polyps.

Authors:  Akira Endo; Hirotaka Koizumi; Makiko Takahashi; Tomohiro Tamura; Shinobu Tatsunami; Yoshiyuki Watanabe; Masayuki Takagi
Journal:  Virchows Arch       Date:  2013-01-06       Impact factor: 4.064

8.  Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients.

Authors:  Sajid A Khan; Melinda Morris; Kamran Idrees; Mark I Gimbel; Shoshana Rosenberg; Zhaoshi Zeng; Fangyong Li; Geliang Gan; Jinru Shia; Michael P LaQuaglia; Philip B Paty
Journal:  J Pediatr Surg       Date:  2016-08-05       Impact factor: 2.545

9.  Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1.

Authors:  Nityanand Maddodi; Kumar M R Bhat; Sulochana Devi; Su-Chun Zhang; Vijayasaradhi Setaluri
Journal:  J Biol Chem       Date:  2009-10-30       Impact factor: 5.157

10.  Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.

Authors:  Narasimhan P Agaram; Grace C Wong; Tianhua Guo; Robert G Maki; Samuel Singer; Ronald P Dematteo; Peter Besmer; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2008-10       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.